Clinical trial · Observational
Relmacabtagene Autoleucel in Hematologic Malignancies
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
NCT06142188CI-TRIAL-00071567not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Large B-cell Lymphoma | — | UNRESOLVED | — |
| Lymphoma, B-Cell | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Relmacabtagene Autoleucel | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Relmacabtagene Autoleucel
- description
- Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
- interventionNames
- Biological: Relmacabtagene Autoleucel
Primary outcomes (1)
- measure
- ORR
- timeFrame
- 15 years
- description
- Percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR);
Secondary outcomes (5)
- measure
- CRR
- timeFrame
- 15 years
- description
- Complete response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed informed consent 2. Patients who have been treated with Relma-cel, including those who have received off-label products; 3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study. Exclusion Criteria: 1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.
References
Publications (0)
Data not yet available
No reference posted for this study.